BR0011891A - Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparso - Google Patents
Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparsoInfo
- Publication number
- BR0011891A BR0011891A BR0011891-5A BR0011891A BR0011891A BR 0011891 A BR0011891 A BR 0011891A BR 0011891 A BR0011891 A BR 0011891A BR 0011891 A BR0011891 A BR 0011891A
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- decrease
- compound
- hpparso
- dense ldl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, MéTODOS PARA TRATAMENTO DE UMA DOENçA OU CONDIçãO MEDIADA PELO HPPARSo , PARA DIMINUIR TRIGLICERìDIOS EM UM PACIENTE, PARA TRATAR A DIABETE DO TIPO 2, DIMINUIR A RESISTêNCIA à INSULINA OU ABAIXAR A PRESSãO SANGUìNEA EM UM PACIENTE, PARA DIMINUIR OS NìVEIS DE FRIBOGêNIO EM UM PACIENTE, PARA DIMINUIR O LDLC EM UM PACIENTE E PARA MUDAR O TAMANHO DA PARTìCULA DO LDL DENSO PEQUENO PARA DENSO NORMAL EM UM PACIENTE, E , USO DE UMA AGONISTA HPPARSo". Compostos da Fórmula (1) são divulgados. Estes compostos incluem ativadores seletivos do PPAR delta humano.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9914977.5A GB9914977D0 (en) | 1999-06-25 | 1999-06-25 | Chemical compounds |
PCT/EP2000/005720 WO2001000603A1 (en) | 1999-06-25 | 2000-06-22 | Thiazole and oxazole derivatives and their pharmaceutical use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0011891A true BR0011891A (pt) | 2002-03-05 |
Family
ID=10856125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0011891-5A BR0011891A (pt) | 1999-06-25 | 2000-06-22 | Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparso |
Country Status (29)
Country | Link |
---|---|
US (2) | US6710063B1 (pt) |
EP (1) | EP1189895B8 (pt) |
JP (2) | JP3490704B2 (pt) |
KR (1) | KR100668026B1 (pt) |
CN (1) | CN1164579C (pt) |
AR (1) | AR035320A1 (pt) |
AT (1) | ATE297384T1 (pt) |
AU (1) | AU765347B2 (pt) |
BR (1) | BR0011891A (pt) |
CA (1) | CA2377126C (pt) |
CO (1) | CO5180622A1 (pt) |
CZ (1) | CZ300654B6 (pt) |
DE (1) | DE60020701T2 (pt) |
ES (1) | ES2243276T3 (pt) |
GB (1) | GB9914977D0 (pt) |
HK (1) | HK1042897B (pt) |
HU (1) | HUP0201858A3 (pt) |
IL (2) | IL146634A0 (pt) |
MX (1) | MXPA01013244A (pt) |
MY (1) | MY120090A (pt) |
NO (1) | NO321872B1 (pt) |
NZ (1) | NZ515676A (pt) |
PE (1) | PE20010406A1 (pt) |
PL (1) | PL353135A1 (pt) |
PT (1) | PT1189895E (pt) |
TR (1) | TR200103612T2 (pt) |
TW (1) | TWI256389B (pt) |
WO (1) | WO2001000603A1 (pt) |
ZA (1) | ZA200109804B (pt) |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0024361D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
GB0024362D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
UA82048C2 (uk) | 2000-11-10 | 2008-03-11 | Эли Лилли Энд Компани | Агоністи альфа-рецепторів, активованих проліфератором пероксисом |
GB0031109D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
US7091225B2 (en) * | 2000-12-20 | 2006-08-15 | Smithkline Beecham Corporation | Substituted oxazoles and thiazoles as hPPAR alpha agonists |
GB0031103D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
GB0031107D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
US20040072838A1 (en) * | 2000-12-20 | 2004-04-15 | Pierette Banker | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors |
US7105551B2 (en) | 2000-12-20 | 2006-09-12 | Smithkline Beecham Corporation | Thiazole derivatives for treating PPAR related disorders |
EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
EP1357914A2 (en) * | 2001-02-02 | 2003-11-05 | SmithKline Beecham Corporation | Treatment of ppar mediated diseases |
US7078422B2 (en) * | 2001-03-23 | 2006-07-18 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator-activated receptor |
WO2002083131A1 (en) * | 2001-04-13 | 2002-10-24 | The Regents Of The University Of California | Activators and ligands of ppar-beta/delta for the treatment of skin conditions |
NZ529033A (en) * | 2001-05-15 | 2005-06-24 | F | Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes |
GB0113231D0 (en) * | 2001-05-31 | 2001-07-25 | Glaxo Group Ltd | Chemical compounds |
KR101106518B1 (ko) | 2001-07-17 | 2012-01-20 | 데이진 가부시키가이샤 | PPAR δ활성화 작용을 측정하는 것을 특징으로 하는 물질의 선택방법 및 약제 |
US6869967B2 (en) | 2001-07-30 | 2005-03-22 | Novo Nordisk A/S | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives |
US7067530B2 (en) | 2001-07-30 | 2006-06-27 | Novo Nordisk A/S | Compounds, their preparation and use |
ATE526319T1 (de) | 2001-08-10 | 2011-10-15 | Nippon Chemiphar Co | Aktivator für den peroxisome proliferator- responsiven rezeptor delta |
AU2002336532C1 (en) * | 2001-09-14 | 2008-10-16 | Amgen, Inc | Linked biaryl compounds |
US7220877B2 (en) | 2001-10-17 | 2007-05-22 | Novo Nordisk A/S | Compounds, their preparation and use |
JP2005528346A (ja) | 2002-02-25 | 2005-09-22 | イーライ・リリー・アンド・カンパニー | ペルオキシソーム増殖因子活性化受容体調節物質 |
AU2003217274A1 (en) | 2002-02-25 | 2003-09-09 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
EP1478630A2 (en) * | 2002-02-28 | 2004-11-24 | SmithKline Beecham Corporation | Process and intermediates for preparing phenylthiomethyl-thiazoles or -oxazoles |
AU2003224632A1 (en) * | 2002-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Hppars activators |
US20030207924A1 (en) * | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
US6833380B2 (en) * | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
US6867224B2 (en) | 2002-03-07 | 2005-03-15 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods of preparation |
US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
KR100474202B1 (ko) * | 2002-05-04 | 2005-03-08 | 강헌중 | 티아졸 유도체의 제조방법 및 이를 제조하기 위한 중간체 |
JP2004277397A (ja) * | 2002-05-24 | 2004-10-07 | Takeda Chem Ind Ltd | 1,2−アゾール誘導体 |
CA2487315A1 (en) * | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
WO2004005266A1 (en) * | 2002-07-03 | 2004-01-15 | F. Hoffmann-La Roche Ag | Oxazole derivatives and their use as insulin sensitizers |
GEP20084475B (en) | 2002-07-09 | 2008-09-10 | Bristol Myers Squibb Co | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method for their production |
DK1537091T3 (da) * | 2002-08-30 | 2010-11-08 | Hoffmann La Roche | Hidtil ukendte 2-arylthiazolforbindelser som PPAR alpha- og PPAR gamma-agonister |
EP1537076A1 (en) | 2002-09-05 | 2005-06-08 | Novo Nordisk A/S | Novel vinyl carboxylic acid derivatives and their therapeutical use |
JP2004123732A (ja) * | 2002-09-10 | 2004-04-22 | Takeda Chem Ind Ltd | 5員複素環化合物 |
US7368578B2 (en) | 2002-09-10 | 2008-05-06 | Takeda Pharmaceutical Company Limited | Five-membered heterocyclic compounds |
ATE345340T1 (de) | 2002-09-12 | 2006-12-15 | Hoffmann La Roche | N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis |
US7162262B2 (en) | 2002-09-23 | 2007-01-09 | Telefonaktiebolaget Lm Ericsson (Publ) | Methods, systems and computer program products for requesting received power levels based on received block error rates utilizing an anti-windup and/or emergency procedure |
US7129268B2 (en) | 2002-10-28 | 2006-10-31 | Novo Nordisk A/S | Peroxisome proliferator activated receptor-active arylene acetic acid derivatives |
US20050080115A1 (en) | 2002-10-28 | 2005-04-14 | Lone Jeppesen | Novel compounds, their preparation and use |
KR20050061562A (ko) | 2002-10-28 | 2005-06-22 | 노보 노르디스크 에이/에스 | 신규 화합물, 그들의 제제 및 사용 |
EP1558571B1 (en) | 2002-10-28 | 2010-06-02 | High Point Pharmaceuticals, LLC | Novel compounds useful in treating ppar mediated diseases |
WO2004041266A1 (ja) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
DE60323130D1 (de) | 2002-11-25 | 2008-10-02 | Hoffmann La Roche | Indolderivaten |
US7816385B2 (en) | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
CA2509202A1 (en) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Fused heterocyclic derivatives as ppar modulators |
DE10308354A1 (de) * | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Cycloalkylderivate mit biosteren Carbonsäure-Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US7148246B2 (en) * | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
US6987118B2 (en) | 2003-05-21 | 2006-01-17 | Pfizer Inc. | Tetrahydroisoquinoline derivatives as PPAR-alpha activators |
DK1670744T5 (da) | 2003-09-19 | 2012-11-26 | Janssen Pharmaceutica Nv | 4-((Phenoxyalkyl)-thio)-phenoxyeddikesyrer og analoge |
EA012241B1 (ru) | 2003-09-19 | 2009-08-28 | Янссен Фармацевтика, Н.В. | 4-((феноксиалкил)тио)феноксиуксусные кислоты и их аналоги |
KR20060121884A (ko) | 2003-09-22 | 2006-11-29 | 오노 야꾸힝 고교 가부시키가이샤 | 페닐초산 유도체, 그 제조 방법 및 용도 |
WO2005051373A1 (ja) | 2003-11-26 | 2005-06-09 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
US20050203151A1 (en) * | 2003-12-19 | 2005-09-15 | Kalypsys, Inc. | Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions |
WO2005063729A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
CN1946666A (zh) | 2004-02-27 | 2007-04-11 | 埃姆艮股份有限公司 | 用于治疗代谢性疾病的化合物、药物组合物和方法 |
JP4813461B2 (ja) | 2004-04-01 | 2011-11-09 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | Pparデルタモジュレーターとしての1,3,4−オキサジアゾール−2−オン、および、それらの使用 |
RU2006138495A (ru) * | 2004-04-01 | 2008-05-10 | Авентис Фармасьютикалз Инк. (Us) | Использование агонистов рецепторов, активируемых пролифератором пероксисомы дельта для лечения рс и других демиелинизирующих заболеваний |
EP1586573B1 (en) | 2004-04-01 | 2007-02-07 | Sanofi-Aventis Deutschland GmbH | Oxadiazolones, processes for their preparation and their use as pharmaceuticals |
JP4813460B2 (ja) * | 2004-04-01 | 2011-11-09 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | PPARδモジュレーターとしての1,3,4−オキサジアゾール−2−オン及びその使用 |
WO2005105736A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Novel compounds, their preparation and use |
ES2352085T3 (es) | 2004-05-05 | 2011-02-15 | High Point Pharmaceuticals, Llc | Nuevos compuestos, su preparación y uso. |
PE20060315A1 (es) * | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
ZA200610650B (en) * | 2004-05-25 | 2009-04-29 | Metabolex Inc | Substituted triazoles as modulators of PPAR and methods of their preparation |
JP2008500358A (ja) * | 2004-05-25 | 2008-01-10 | メタボレックス インコーポレーティッド | Pparのモジュレーターとしての、二環式の置換されたトリアゾール、およびこれらの調製方法 |
JP2007269630A (ja) * | 2004-06-23 | 2007-10-18 | Toudai Tlo Ltd | インスリン分泌促進剤 |
MY147518A (en) | 2004-09-15 | 2012-12-31 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
WO2006043797A1 (en) * | 2004-10-22 | 2006-04-27 | Heonjoong Kang | Process for alkyl aryl sulfide derivatives and new sulfide compounds |
CA2590533C (en) * | 2004-11-23 | 2010-09-07 | Warner-Lambert Company Llc | 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia |
US20080051418A1 (en) * | 2004-11-26 | 2008-02-28 | Tsuyoshi Maekawa | Arylalkanoic Acid Derivative |
KR100753860B1 (ko) * | 2004-12-31 | 2007-08-31 | 재단법인서울대학교산학협력재단 | 유기 셀레늄 함유 화합물 및 이들 화합물의 용도 |
EP1841748B1 (en) * | 2004-12-31 | 2011-12-28 | Seoul National University Industry Foundation | Organoselenium containing compounds and their use |
FR2880886B1 (fr) * | 2005-01-14 | 2007-04-06 | Merck Sante Soc Par Actions Si | Derives de l'acide 6-phenylhex-5-enoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique |
BRPI0606232A2 (pt) * | 2005-02-25 | 2009-06-09 | Kang Heonjoong | derivados de tiazole como os ligantes delta ppar e seus processos de produção |
WO2006121223A1 (en) * | 2005-05-07 | 2006-11-16 | Heon Joong Kang | Process for preparing ligands of ppardelta and the intermediate compounds for preparing the same |
US7465804B2 (en) * | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
US7781469B2 (en) | 2005-05-27 | 2010-08-24 | Shionogi & Co., Ltd. | Arylacetate derivatives having isoxazole skeleton |
WO2006126541A1 (ja) * | 2005-05-27 | 2006-11-30 | Shionogi & Co., Ltd. | ビタミンk類含有医薬組成物 |
KR101333101B1 (ko) | 2005-06-30 | 2013-11-26 | 하이 포인트 파마슈티칼스, 엘엘씨 | Ppar-델타 활성제로서의 페녹시 아세트산 |
JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
CA2621949A1 (en) * | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
AU2006299091A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
JP5183479B2 (ja) * | 2005-09-29 | 2013-04-17 | サノフイ | フェニル基を有するフェニル−[1,2,4]−オキサジアゾール−5−オン誘導体、その製造方法、及び医薬品としてのその使用 |
US7943613B2 (en) | 2005-12-22 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
WO2007127502A2 (en) * | 2006-01-10 | 2007-11-08 | Smithkline Beecham Corporation | Polymorphic form of { 2-methyl-4- [ 4-methyl-2- ( 4-triflu0r0methylphenyl) thiazol -5- ylmethylthiol phenoxy }-acetic acid |
CN101007790B (zh) * | 2006-01-27 | 2011-03-30 | 北京摩力克科技有限公司 | 草氨酸衍生物、其制备方法和医药用途 |
AU2007212126B2 (en) * | 2006-02-03 | 2012-07-19 | Eli Lilly And Company | Compounds and methods for modulating FX-receptors |
JP2009132620A (ja) * | 2006-03-07 | 2009-06-18 | Astellas Pharma Inc | フェニルチアゾール誘導体 |
CA2645719A1 (en) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Compounds that modulate ppar activity, their preparation and use |
CA2646430A1 (en) * | 2006-03-14 | 2007-09-20 | Amgen Inc. | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders |
PT2014652E (pt) * | 2006-04-18 | 2014-11-12 | Nippon Chemiphar Co | Agente de ativação para o recetor ativado por proliferador de peroxissoma |
PE20080188A1 (es) | 2006-04-18 | 2008-03-10 | Janssen Pharmaceutica Nv | Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol |
WO2007141295A1 (en) * | 2006-06-08 | 2007-12-13 | High Point Pharmaceuticals, Llc | Process for preparing phenoxy acetic acid derivatives |
US20080004281A1 (en) * | 2006-06-28 | 2008-01-03 | Kalypsys, Inc. | Methods for the modulation of crp by the selective modulation of ppar delta |
WO2008016175A1 (fr) * | 2006-08-03 | 2008-02-07 | Nippon Chemiphar Co., Ltd. | Agent activant de récepteur activé par les proliférateurs des peroxysomes |
CA2662242C (en) * | 2006-09-07 | 2012-06-12 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
EP2064193A1 (en) * | 2006-09-07 | 2009-06-03 | Amgen, Inc | Heterocyclic gpr40 modulators |
US9717719B2 (en) * | 2006-09-08 | 2017-08-01 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced liver disease |
AU2007292883B2 (en) | 2006-09-08 | 2013-09-05 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced brain disease |
CN103086936A (zh) | 2006-12-02 | 2013-05-08 | 财团法人首尔大学校产学协力财团 | 作为ppar配体的芳基化合物及其用途 |
JP2010514804A (ja) | 2006-12-29 | 2010-05-06 | ザ・ソーク・インスティチュート・フォー・バイオロジカル・スタディーズ | 運動能力を高めるための方法 |
KR100954237B1 (ko) | 2007-01-08 | 2010-04-21 | 재단법인서울대학교산학협력재단 | 퍼록시솜 증식자 활성화 수용체 델타 리간드 티아졸 화합물및 이를 함유하는 의약, 화장품 및 건강식품 조성물 |
MX2009008923A (es) * | 2007-02-22 | 2009-08-28 | Irm Llc | Compuestos y metodos para modular receptores acoplados por proteina g. |
EP2139843B1 (en) | 2007-04-16 | 2013-12-25 | Amgen, Inc | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
WO2008154023A1 (en) * | 2007-06-11 | 2008-12-18 | Cerenis Therapeutics S.A. | Novel uses of ppar delta agonists |
GB0712653D0 (en) | 2007-06-28 | 2007-08-08 | Syngenta Ltd | Novel herbicides |
GB0717082D0 (en) | 2007-09-03 | 2007-10-10 | Syngenta Ltd | Novel herbicides |
MX2010003876A (es) | 2007-10-10 | 2010-12-02 | Amgen Inc | Moduladores de gpr40 bifenilo- sustituidos. |
CA2708391A1 (en) * | 2007-12-13 | 2009-06-25 | Sri International | Ppar-delta ligands and methods of their use |
EP2260017A1 (en) * | 2008-03-06 | 2010-12-15 | Amgen, Inc | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
SI2277874T1 (sl) | 2008-04-15 | 2019-01-31 | Nippon Chemiphar Co., Ltd. | Aktivator za peroksisomski proliferator-aktiviran receptor |
CN101643451B (zh) | 2008-08-07 | 2013-03-06 | 浙江海正药业股份有限公司 | 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法 |
US8748462B2 (en) | 2008-10-15 | 2014-06-10 | Amgen Inc. | Spirocyclic GPR40 modulators |
ES2712052T3 (es) | 2008-10-17 | 2019-05-09 | Cymabay Therapeutics Inc | Métodos para reducir partículas de LDL pequeñas y densas |
EP2540711A4 (en) * | 2010-02-25 | 2014-01-22 | Snu R&Db Foundation | SELENAZOLE DERIVATIVE HAVING A LIGAND THAT ACTIVATES THE ACTIVATED RECEPTOR OF PEROXISOME PROLIFERATION (PPAR), ITS PREPARATION METHOD AND THE USE OF CHEMICAL COMPOUNDS |
CN102285933B (zh) * | 2010-06-18 | 2016-03-09 | 浙江海正药业股份有限公司 | 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用 |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
CA2809958A1 (en) * | 2010-08-31 | 2012-03-08 | Snu R & Db Foundation | Use of the fetal reprogramming of a ppar ? agonist |
US10181018B2 (en) * | 2013-03-14 | 2019-01-15 | The University Of Toledo | Analogs of proxisome proliferator activated receptor (PPAR) agonists and methods of using the same |
WO2014152809A2 (en) * | 2013-03-14 | 2014-09-25 | The University Of Toledo | Analogs of pparo and 20-oh-pge2, and methods of using the same |
WO2015035171A1 (en) | 2013-09-09 | 2015-03-12 | High Point Pharmaceuticals, Llc | Use of a ppar-delta agonist for treating muscle atrophy |
US20220031666A1 (en) * | 2018-10-23 | 2022-02-03 | Japan Science And Technology Agency | PPARo ACTIVATOR |
US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
WO2022189856A1 (en) * | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS644688A (en) * | 1987-06-26 | 1989-01-09 | Tokuyama Soda Kk | Photochromic composition |
JPH0793082B2 (ja) * | 1987-09-07 | 1995-10-09 | 株式会社明電舎 | 真空インタラプタの化成方法 |
JP2551151B2 (ja) * | 1989-06-22 | 1996-11-06 | 神鋼電機株式会社 | 潜熱回収方式の給湯装置における放熱装置 |
JP3039009B2 (ja) * | 1991-06-25 | 2000-05-08 | ソニー株式会社 | 固体撮像素子の駆動装置 |
TW268952B (pt) | 1993-02-26 | 1996-01-21 | Takeda Pharm Industry Co Ltd | |
JP3466273B2 (ja) | 1993-06-11 | 2003-11-10 | 武田薬品工業株式会社 | テトラゾール誘導体、その製造法およびそれを含んでなる医薬 |
US5591862A (en) * | 1993-06-11 | 1997-01-07 | Takeda Chemical Industries, Ltd. | Tetrazole derivatives, their production and use |
JP3836521B2 (ja) | 1994-08-10 | 2006-10-25 | 武田薬品工業株式会社 | 2,4−チアゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物 |
JP2850809B2 (ja) | 1994-11-02 | 1999-01-27 | 武田薬品工業株式会社 | 2,4−オキサゾリジンジオン誘導体およびそれを含んでなる医薬組成物 |
JP3880108B2 (ja) | 1994-11-02 | 2007-02-14 | 武田薬品工業株式会社 | 2,4−オキサゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物 |
JPH08325250A (ja) | 1995-05-31 | 1996-12-10 | Sumitomo Metal Ind Ltd | 新規置換フェノール誘導体 |
JPH08325263A (ja) * | 1995-05-31 | 1996-12-10 | Sumitomo Metal Ind Ltd | 新規2−アミノ−3−フェニルプロピオン酸誘導体 |
US5847008A (en) | 1996-02-02 | 1998-12-08 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
AU1856997A (en) * | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
JP3215048B2 (ja) | 1996-04-03 | 2001-10-02 | 日本たばこ産業株式会社 | プロピオン酸誘導体及びその用途 |
PL331861A1 (en) * | 1996-08-19 | 1999-08-16 | Japan Tobacco Inc | Derivatives of propionic acid and their application |
JP4427825B2 (ja) * | 1997-07-24 | 2010-03-10 | アステラス製薬株式会社 | コレステロール低下作用を有する医薬組成物 |
AU3275999A (en) * | 1998-03-10 | 1999-09-27 | Ono Pharmaceutical Co. Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
KR102220553B1 (ko) * | 2015-03-10 | 2021-02-26 | 한국전자통신연구원 | 표시 패널 및 그것을 포함하는 표시 장치 |
-
1999
- 1999-06-25 GB GBGB9914977.5A patent/GB9914977D0/en not_active Ceased
-
2000
- 2000-06-22 CA CA002377126A patent/CA2377126C/en not_active Expired - Fee Related
- 2000-06-22 JP JP2001507012A patent/JP3490704B2/ja not_active Expired - Fee Related
- 2000-06-22 NZ NZ515676A patent/NZ515676A/en not_active IP Right Cessation
- 2000-06-22 US US10/018,935 patent/US6710063B1/en not_active Expired - Fee Related
- 2000-06-22 DE DE60020701T patent/DE60020701T2/de not_active Expired - Lifetime
- 2000-06-22 AT AT00943847T patent/ATE297384T1/de not_active IP Right Cessation
- 2000-06-22 AU AU58171/00A patent/AU765347B2/en not_active Ceased
- 2000-06-22 ES ES00943847T patent/ES2243276T3/es not_active Expired - Lifetime
- 2000-06-22 PT PT00943847T patent/PT1189895E/pt unknown
- 2000-06-22 CN CNB008094969A patent/CN1164579C/zh not_active Expired - Fee Related
- 2000-06-22 CZ CZ20014664A patent/CZ300654B6/cs not_active IP Right Cessation
- 2000-06-22 WO PCT/EP2000/005720 patent/WO2001000603A1/en active IP Right Grant
- 2000-06-22 BR BR0011891-5A patent/BR0011891A/pt active Search and Examination
- 2000-06-22 KR KR1020017016616A patent/KR100668026B1/ko not_active IP Right Cessation
- 2000-06-22 HU HU0201858A patent/HUP0201858A3/hu unknown
- 2000-06-22 TR TR2001/03612T patent/TR200103612T2/xx unknown
- 2000-06-22 MX MXPA01013244A patent/MXPA01013244A/es active IP Right Grant
- 2000-06-22 IL IL14663400A patent/IL146634A0/xx active IP Right Grant
- 2000-06-22 EP EP00943847A patent/EP1189895B8/en not_active Expired - Lifetime
- 2000-06-22 PL PL00353135A patent/PL353135A1/xx not_active Application Discontinuation
- 2000-06-23 PE PE2000000630A patent/PE20010406A1/es not_active Application Discontinuation
- 2000-06-23 CO CO00047291A patent/CO5180622A1/es not_active Application Discontinuation
- 2000-06-23 AR ARP000103161A patent/AR035320A1/es active IP Right Grant
- 2000-06-23 MY MYPI20002859A patent/MY120090A/en unknown
- 2000-06-28 TW TW089112727A patent/TWI256389B/zh not_active IP Right Cessation
-
2001
- 2001-11-20 IL IL146634A patent/IL146634A/en not_active IP Right Cessation
- 2001-11-28 ZA ZA200109804A patent/ZA200109804B/en unknown
- 2001-12-13 NO NO20016078A patent/NO321872B1/no not_active IP Right Cessation
-
2002
- 2002-06-11 HK HK02104378.2A patent/HK1042897B/zh not_active IP Right Cessation
-
2003
- 2003-03-06 US US10/383,011 patent/US6723740B2/en not_active Expired - Fee Related
- 2003-04-01 JP JP2003098492A patent/JP2003313141A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0011891A (pt) | Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparso | |
BR0116370A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente. | |
BR0012136A (pt) | Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos | |
BR0015974A (pt) | Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto | |
BRPI0317463B8 (pt) | composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina | |
BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
BR0206985A (pt) | Anticorpos modificados e métodos de uso | |
BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
BRPI0412526A (pt) | composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica | |
BR0010651A (pt) | Composto, uso de um composto, composição farmacêutica, e, método para o tratamento e/ou prevenção de distúrbios ou de doenças mediadas por uma ação antagonìstica de glucagon | |
BR0009864A (pt) | Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto | |
BRPI0407757A (pt) | derivados de benzamida tetracìclica e métodos de uso dos mesmos | |
BR9906813A (pt) | Método para administração de insulina aspb28- humana | |
EA200300776A1 (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
BR0015294A (pt) | Método para tratamento da diabetes | |
BR0311313A (pt) | Derivados de diaril uréia úteis para o tratamento de doenças dependentes de proteìna cinase | |
BR9809968A (pt) | Aplicação de derivados tiazolidinadiona no tratamento da pcos e diabetes gestacional | |
BR9811825A (pt) | Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue | |
MY145590A (en) | Phenylacetamides and their use as glucokinase modulators | |
EA200000759A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
BRPI0408229A (pt) | preparação farmacêutica, métodos para preparar um ligando de ligação de zinco, para prolongar a ação de uma preparação de insulina estabilizada por ácido e para tratar diabete do tipo 1 ou tipo 2, e, uso de uma preparação | |
NO20050569L (no) | Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette | |
BR0309278A (pt) | Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto | |
BRPI0612840A8 (pt) | Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções | |
BR9813651A (pt) | Compostos antipicornavirais e métodos para o seu uso e preparação |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DE INT.CL: C07D 277/24, C07D 277/26, C07D 263/32, A61K 31/421, A61K 31/426, A61P 3/10 Ipc: A61K 31/421 (2009.01), A61K 31/422 (2009.01), A61K |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |